http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html Thu, 18 Jun 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html Thu, 18 Jun 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html Thu, 18 Jun 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html <p> NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company’s common stock to seven newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26663287.html Thu, 18 Jun 2026 08:30:00 -0400 O.46871614 SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/Press+Releases/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html <div class="xn-content"> <p><i>Issued on behalf of <span value="NASDAQ-NMS:HYFT" idsrc="xmltag.org" >MindWalk Holdings Corp.</span></i></p><p><i>Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.</i></p><p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://equity-insider.com/" target="_blank" rel="nofollow">Equity Insider</a> News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, http://www.streetinsider.com/PRNewswire/The+Quiet+Bottleneck+in+AI+Drug+Discovery+Isn%27t+the+Model+--+It%27s+the+Biology+Underneath+It/26651167.html Tue, 16 Jun 2026 08:45:00 -0400 ABSI CERT HYFT O.02598349 O.34383149 O.46871614 O.49399309 O.51016270 RXRX SDGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+Jun+05/26617686.html si-local-file:///var/storage/secattach/20260608/26617686.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Schrodinger%2C+Inc.+++++++++For%3A+Jun+05/26617686.html Mon, 08 Jun 2026 16:23:00 -0400 O.46871614 SDGR